MRgLITT Mesencephalotomy for Refractory Malignant Pain Management
Overview
This report details the first robot-assisted MR-guided laser interstitial thermal therapy (MRgLITT) mesencephalotomy performed on a patient with metastatic melanoma and refractory pain. The procedure resulted in significant pain reduction without neurological deficits, demonstrating MRgLITT's potential as a minimally invasive option for intractable malignant pain.
Background
Stereotactic mesencephalotomy targets spinothalamic and trigeminothalamic pathways to alleviate intractable pain but declined due to morbidity and neuromodulation advances. Recent imaging and minimally invasive technologies like MRgLITT have renewed interest by offering precise, real-time image-guided lesioning. MRgLITT may provide effective palliative pain management with fewer complications. This case represents the first documented use of robot-assisted MRgLITT mesencephalotomy for malignant pain.
Data Highlights
Parameter
Value
Patient Age
47 years
Preoperative Pain Score (VAS)
>7
Postoperative Pain Score (VAS)
<3
Ablation Zone Diameter
~5 mm
Laser Power Settings
1.0 W, 1.5 W, 2.0 W (each for 2 min)
Follow-up Duration
1 month (patient deceased due to cancer progression)
Key Findings
MRgLITT mesencephalotomy was successfully performed using robotic assistance and real-time MRI thermometry for precise lesioning of the spinothalamic tract.
The procedure significantly reduced pain scores from >7 to <3 on the visual analog scale without causing neurological deficits.
Thermal sensation was preserved postoperatively, indicating selective lesioning without sensory discrimination loss.
Postoperative imaging confirmed a well-defined lesion with no damage to adjacent critical structures.
Opioid and adjunctive medication requirements were substantially reduced following the procedure.
The patient died one month later due to cancer progression, limiting long-term outcome assessment.
Clinical Implications
MRgLITT mesencephalotomy offers a minimally invasive, image-guided approach to treat refractory malignant pain, especially when other interventions are unsuitable. Its precision and safety profile make it a valuable option in palliative care to improve quality of life. Multidisciplinary evaluation is essential for patient selection and individualized treatment planning.
Conclusion
This first documented case of robot-assisted MRgLITT mesencephalotomy demonstrates its feasibility, safety, and efficacy in managing intractable malignant pain. MRgLITT represents a promising technique warranting further study for broader clinical application.
References
Historical and technical context of mesencephalotomy and MRgLITT
For years, chronic stroke patients heard familiar feedback regarding their ability to regain strength and mobility after ischemic strokes caused upper-extremity deficits.
